{
    "2018-11-14": [
        [
            {
                "time": "2018-01-01",
                "original_text": "Awaits D-Day, AMEH In Good Health, AXSM To Report ASCEND Data In Jan.",
                "features": {
                    "keywords": [
                        "AMEH",
                        "AXSM",
                        "ASCEND Data"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie (ABBV) Gains As Market Dips: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "market dips"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Elagolix",
                        "Phase 3 Data"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Sobi",
                        "Lung Infection Drug"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Mavyret",
                        "Label Expansion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "CLASS ACTION UPDATE for ABBV, CHGG and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "features": {
                    "keywords": [
                        "Class Action",
                        "ABBV"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "Schall Law Firm",
                        "Class Action",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV",
                "features": {
                    "keywords": [
                        "Bernstein Liebhard LLP",
                        "Class Action",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "IWF, KO, PEP, ABBV: ETF Inflow Alert",
                "features": {
                    "keywords": [
                        "ETF Inflow",
                        "ABBV"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018",
                "features": {
                    "keywords": [
                        "Bronstein, Gewirtz & Grossman",
                        "Class Action",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Zacks Analyst Blog Highlights: Berkshire Hathaway, AbbVie, Booking, HCA and Kimberly-Clark",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diversified"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}